BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Financial News

Co.don raises EUR15.5M private placement

...On Oct. 20, co.don AG (Xetra:CNWK) raised €15.5 million ($18.3 million) through the sale of 1.8 million...
...through the sale of 1.8 million shares at €8.75 in a private placement. In September, co.don...
...to treat cartilage repair. Spherox comprises spherical aggregates of autologous chondrocytes. co.don AG (Xetra:CNWK), Berlin, Germany Jennie Walters Spherox co.don AG...
BioCentury | Dec 7, 2015
Financial News

co.don completes rights offering

co.don AG (Xetra:CNWK), Berlin, Germany Business: Musculoskeletal Date completed: 2015-11-26 Type: Rights offering Raised: EUR5 million ($5.3 million) Shares: 2.5 million Price: EUR2 Shares after offering: 16.2 million Investors: Existing investors; new investors Note: Shareholders...
BioCentury | Nov 9, 2015
Financial News

co.don proposes rights offering

co.don AG (Xetra:CNWK), Berlin, Germany Business: Musculoskeletal Date announced: 2015-11-03 Type: Rights offering To be raised: EUR5 million ($5.5 million) Shares: 2.5 million Price: EUR2 Shares outstanding prior: 13.7 million Investor: Existing investors Note: Shareholders...
BioCentury | May 8, 2006
Company News

Co.don, Xmedica sales and marketing update

...CNW granted Xmedica exclusive Italian distribution rights to co.don chondrotransplant and co.don chondrotransplant DISC , which...
...deal, Xmedica also received rights to co.don chondrosphere , a cultured autologous matrix-supported articular cartilage. co.don AG...
BioCentury | Apr 3, 2006
Company News

Co.don, Encore Medical Corp. sales and marketing update

...Parchim, Germany) exclusive German distribution rights to co.don chondrosphere cultured autologous matrix-supported articular cartilage and co.don...
...an autologous intervertebral disc-derived chondrocyte transplant. Financial terms of the three-year deal were not disclosed. co.don AG...
BioCentury | Oct 31, 2005
Clinical News

Co: Interim Phase III data

...the affected and treated intervertebral disc was lower than control. co.don AG (FSE:CNW), Berlin, Germany Product: Co.don...
BioCentury | Oct 24, 2005
Finance

Ebb & Flow

...FDA handles the companies' sBLA for Tysabri to treat MS, which was submitted in September. co.don...
...a roller coaster ride in front of last Friday's interim Phase III data for its co.don...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...B15). On the week, AVNC was up $1.18 (127%) to $2.11. London & the Continent Co.don...
BioCentury | Aug 15, 2005
Finance

TVM IPOs

...Ark (LSE:AKT) Drugs for cancer and cardiovascular disease Biocompatibles (LSE:BII) Medical devices and drug delivery co.don...
Items per page:
1 - 10 of 34
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Financial News

Co.don raises EUR15.5M private placement

...On Oct. 20, co.don AG (Xetra:CNWK) raised €15.5 million ($18.3 million) through the sale of 1.8 million...
...through the sale of 1.8 million shares at €8.75 in a private placement. In September, co.don...
...to treat cartilage repair. Spherox comprises spherical aggregates of autologous chondrocytes. co.don AG (Xetra:CNWK), Berlin, Germany Jennie Walters Spherox co.don AG...
BioCentury | Dec 7, 2015
Financial News

co.don completes rights offering

co.don AG (Xetra:CNWK), Berlin, Germany Business: Musculoskeletal Date completed: 2015-11-26 Type: Rights offering Raised: EUR5 million ($5.3 million) Shares: 2.5 million Price: EUR2 Shares after offering: 16.2 million Investors: Existing investors; new investors Note: Shareholders...
BioCentury | Nov 9, 2015
Financial News

co.don proposes rights offering

co.don AG (Xetra:CNWK), Berlin, Germany Business: Musculoskeletal Date announced: 2015-11-03 Type: Rights offering To be raised: EUR5 million ($5.5 million) Shares: 2.5 million Price: EUR2 Shares outstanding prior: 13.7 million Investor: Existing investors Note: Shareholders...
BioCentury | May 8, 2006
Company News

Co.don, Xmedica sales and marketing update

...CNW granted Xmedica exclusive Italian distribution rights to co.don chondrotransplant and co.don chondrotransplant DISC , which...
...deal, Xmedica also received rights to co.don chondrosphere , a cultured autologous matrix-supported articular cartilage. co.don AG...
BioCentury | Apr 3, 2006
Company News

Co.don, Encore Medical Corp. sales and marketing update

...Parchim, Germany) exclusive German distribution rights to co.don chondrosphere cultured autologous matrix-supported articular cartilage and co.don...
...an autologous intervertebral disc-derived chondrocyte transplant. Financial terms of the three-year deal were not disclosed. co.don AG...
BioCentury | Oct 31, 2005
Clinical News

Co: Interim Phase III data

...the affected and treated intervertebral disc was lower than control. co.don AG (FSE:CNW), Berlin, Germany Product: Co.don...
BioCentury | Oct 24, 2005
Finance

Ebb & Flow

...FDA handles the companies' sBLA for Tysabri to treat MS, which was submitted in September. co.don...
...a roller coaster ride in front of last Friday's interim Phase III data for its co.don...
BioCentury | Sep 19, 2005
Finance

Ebb & Flow

...B15). On the week, AVNC was up $1.18 (127%) to $2.11. London & the Continent Co.don...
BioCentury | Aug 15, 2005
Finance

TVM IPOs

...Ark (LSE:AKT) Drugs for cancer and cardiovascular disease Biocompatibles (LSE:BII) Medical devices and drug delivery co.don...
Items per page:
1 - 10 of 34